Johns Hopkins MedicineCOVID-19 Vaccine Hesitancy: 12 Things You Need to Know

Despite many doing their research and learning all they can about the COVID-19 vaccine, patients may still come to you for more help. To assist your patients with their questions about the COVID-19 vaccine, here are 12 facts and insights shared by Sherita Golden, MD, MHS, chief diversity officer at Johns Hopkins Medicine, who specializes […]

American Academy of PediatricsCDC Confirms 226 Cases of Myocarditis After COVID-19 Vaccination in People 30 and Under

The data was presented to the FDA, which reported 789 cases of myocarditis/pericarditis – predominantly in males – after receiving the Pfizer/BioNTech and Moderna vaccines, most commonly after the second dose. Symptoms included chest pain, elevated cardiac enzymes, ST or T wave changes, dyspnea, and abnormal echocardiography/imaging for those ages 30 years and younger.

M3Common IBS/IBD Treatment Blunts COVID-19 Vaccine Response

The research, taken from the CLARITY study and published in GUT, found that 865 people given the Pfizer/BioNTech or the Oxford/AZ COVID-19 vaccine and treated with infliximab (Remicade) had significantly lower concentrations of antibodies when compared to 428 people on an alternative treatment, vedolizumab (Entyvio). Infliximab is prescribed to around two million people worldwide.

American Society of HematologyEfficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia

This Research Article from Blood – available as a PDF – discusses two main points. First, antibody response to BNT162b2 mRNA COVID19 vaccine in CLL patients is markedly impaired and affected by disease activity and treatment. The second point shows that, in patients treated with either Bruton’s tyrosine kinase inhibitors (TKIs) or venetoclax ± anti-CD20 […]

Everyday HealthCancer Patients Respond Poorly to First COVID mRNA Vax Dose

The data, concluded in a report posted to the preprint server medRxiv, support prioritization of cancer patients for an early (21-day) second dose of the BNT162b2 vaccine, as barely one-quarter of patients with cancer obtained protection (28% immune efficacy rate, including 13% in patients with blood cancers) against COVID-19 after one dose of the Pfizer/BioNTech […]